---
title: "Eyepoint Phase 3 setback: Duravyu fails to maintain vision with less-frequent injections in wet AMD"
id: "stat-news-1-stat-eyepoint-study-results-for-vision-treatment-disappoint-but-company-still"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-eyepoint-study-results-for-vision-treatment-disappoint-but-company-still"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/08/17/eyepoint-duravyu-wet-amd-study/?utm_campaign=rss"
published_at: "2026-08-17T18:45:42.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Eyepoint Phase 3 setback: Duravyu fails to maintain vision with less-frequent injections in wet AMD
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-eyepoint-study-results-for-vision-treatment-disappoint-but-company-still
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/08/17/eyepoint-duravyu-wet-amd-study/?utm_campaign=rss)
- **Published At:** 2026-08-17T18:45:42.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Eyepoint reported that its Phase 3 trial of the experimental therapy **Duravyu** for **wet age-related macular degeneration (wet AMD)** did not meet its primary endpoint: patients given the drug with less-frequent injections failed to maintain vision compared with a standard treatment. - The trial outcome threatens Eyepoint’s plan to seek regulatory approval for Duravyu and prompted a sharp decline in the company’s stock price, per the source. - Shares of competitor **Ocular Therapeutix** rose after the news; Ocular’s rival treatment is expected to be submitted to the FDA later in the year. - Both Eyepoint and Ocular are developing therapies intended to maintain vision in people with **wet AMD** with the advantage of requiring injections less frequently than currently approved options. - The STAT News story is a STAT+ exclusive; full article content beyond the summary was behind the STAT+ paywall in the source. - The source did not report many trial details in the accessible portion: it did not provide numerical results, the exact primary endpoint definition, sample size, statistical significance, safety data, dosing schedules, or timelines for Eyepoint’s regulatory submissions. - The author of the source article is Adam Feuerstein and the item was published Aug. 17, 2026. The piece framed the clinical result as a setback that has commercial and regulatory implications in a competitive field of longer-acting intravitreal therapies for **wet AMD**.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/08/17/eyepoint-duravyu-wet-amd-study/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/17/eyepoint-duravyu-wet-amd-study/?utm_campaign=rss) [legal](https://www.statnews.com/topic/legal/) [states](https://www.statnews.com/topic/states/) [Hospitals](https://www.statnews.com/category/hospitals/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Eyepoint study results for vision treatment disappoint, but company still sees promise ## Data could imperil biotech’s plans to seek regulatory approval in competitive field * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/17/eyepoint-duravyu-wet-amd-study/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2024/09/AdobeStock_138806370-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Aug. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of [Adam’s Biotech Scorecard](https://www.statnews.com/signup/scorecard/), a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. Eyepoint said Monday that patients administered its experimental treatment for a common cause of age-related blindness failed to maintain vision with less frequent injections compared to a standard treatment — meaning a Phase 3 clinical trial had fallen short of its primary goal. The study setback imperiled Eyepoint’s plans to seek regulatory approval for the drug, Duravyu, and caused its stock price to plummet. Shares of Ocular Therapeutix, the maker of a competing eye treatment that will be submitted to the Food and Drug Administration later this year, rose in reaction. Advertisement Both Eyepoint and Ocular are developing drugs to maintain vision in people with wet age-related macular degeneration, or wet AMD; those drugs can be injected into the eye less frequently than currently approved treatments. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [drug development](https://www.statnews.com/topic/drug-development/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") 2. Senior Writer, Biotech 1. [](https://x.com/adamfeuerstein "X") 2. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2024/03/Biotech-Scorecard-Logo-NoSTAT-640x290.png) ### STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_409379202_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [UnitedHealth faces IRS probe over potential tax avoidance](https://www.statnews.com/2026/08/17/unitedhealth-irs-probe-audit-targets-foreign-subsidiary-transfers/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/STAT_EpicExodus_F1_3000_REV-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Epic confronts unprecedented challenges as it prepares to address customers and unveil road map](https://www.statnews.com/2026/08/17/ugm-epic-confronts-challenges-succession-ai-strategy-antitrust/) 3. ![](https://www.statnews.com/wp-content/uploads/2024/06/AP24158651812213-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Epic’s alleged anticompetitive practices under scrutiny from federal, state investigators](https://www.statnews.com/2026/08/14/epic-systems-ftc-review-nda-use-possible-anticompetitive-practices/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_2070510066-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [State laws may be curbing private equity takeovers of physician group](https://www.statnews.com/2026/08/17/private-equity-50-percent-drop-physician-practice-management-deals-2026/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_845818699-80x80.jpeg) [We proved bipartisan health care reform works in North Carolina. Let’s bring it nationwide](https://www.statnews.com/2026/08/17/healthy-opportunities-pilots-hop-program-north-carolina-medicaid-social-services/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2025/08/VCFirms2025_LeftRailUnit-328x426.png) 2025 Edition: Ranking Biotech’s Top Venture Capital Firms ](https://reports.statnews.com/products/biotech-top-venture-capital-firms-2025) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/STAT_AIBillingSystem_F1_3000-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care](https://www.statnews.com/2026/08/12/inside-commure-athelas-mad-dash-automate-health-care/) 2. ![](https://www.statnews.com/wp-content/uploads/2023/04/AdobeStock_521699065_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment](https://www.statnews.com/2026/08/10/itm-radiopharma-fda-rejection/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/Schett-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies](https://www.statnews.com/2026/08/12/boulevard-bio-georg-schett-antibody-therapies/) 4. ![](https://www.statnews.com/wp-content/uploads/2022/12/AdobeStock_251916311-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class](https://www.statnews.com/2026/08/14/fda-approves-bristol-multiple-myeloma-drug-zenbexus/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2269935478-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed](https://www.statnews.com/2026/08/10/china-biotech-new-scrutiny-investigator-initiated-trials/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout August 17, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit ](https://www.statnews.com/2026/08/17/biotech-news-akeso-summit-ivonescimabs-worsening-tumor-progression-benefit/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout August 14, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: PBMs agree to display TrumpRx drug prices ](https://www.statnews.com/2026/08/14/biotech-news-pbms-agree-to-display-trumprx-drug-prices/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech August 14, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class ](https://www.statnews.com/2026/08/14/fda-approves-bristol-multiple-myeloma-drug-zenbexus/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout August 13, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Eli Lilly targets booming black market for retatrutide ](https://www.statnews.com/2026/08/13/biotech-news-eli-lilly-targets-booming-retatrutide-black-market/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard August 13, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Neurocrine Biosciences and the delicate balance of benefit and risk ](https://www.statnews.com/2026/08/13/neurocrine-biosciences-vykat-prader-willi-2/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care ](https://www.statnews.com/2026/08/12/inside-commure-athelas-mad-dash-automate-health-care/) By [Casey Ross](https://www.statnews.com/staff/casey-ross/) and [Brittany Trang](https://www.statnews.com/staff/brittany-trang/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: The promise of radiopharmaceuticals smacks into safety concerns ](https://www.statnews.com/2026/08/10/radiopharmaceuticals-clinical-trials-progress-setbacks/) By [Allison DeAngelis](https://www.statnews.com/staff/a
## Related Clinical Research

- [Massachusetts hospital CEOs saw large pay increases in 2024, Mass General Brigham CEO tops list](https://medichelpline.com/clinical-feed/stat-news-2-stat-leaders-of-mass-general-dana-farber-among-hospital-execs-who-got-big.md)
- [How rising health care costs are straining America’s public-sector employers](https://medichelpline.com/clinical-feed/stat-news-4-stat-how-health-care-costs-are-undermining-america-s-public-sector-employers.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)
- [Coffee consumption associated with lower visceral fat, higher muscle mass, and hormonal differences](https://medichelpline.com/clinical-feed/medical-news-today-0-coffee-drinking-linked-to-less-abdominal-fat-more-muscle-better-hormone-balance.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.